ALiEM - Pharm Pearls
OCTOBER 30, 2024
Bupe Allergy Buprenorphine induction has been the mainstay of emergency department treatment of opioid use disorder for more than a decade [11, 12]. Of note, screening is often required for insurance approval for substance use treatment. 2024 study [16]. Prolonged QTc was defined as >450 msec.
Pharmacy Times
JULY 21, 2025
Cardiovascular disease risks in HIV patients have evolved with ART, requiring preventive measures like statins and cardiovascular risk scores for effective management. Healthy aging in HIV patients involves addressing accelerated aging, multimorbidity, and geriatric syndromes, emphasizing functional ability and quality of life.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 16, 2025
Tarlatamab established a new standard for relapsed SCLC, with improved survival and easier administration, enhancing treatment accessibility. 2 Vepdegestrant is an oral PROTAC that targets ER and is the first agent of its type to be evaluated in a phase 3 trial. months; HR, 0.57; 95% CI, 0.42-0.77) months; HR, 0.83; 95% CI, 0.68-1.02).
Pharmacy Times
JULY 18, 2025
Image credit: OM | stock.adobe.com Why Proper Disposal Matters Disposing of medications appropriately helps prevent environmental contamination of water and soil. Updated November 14, 2024. Safe disposal options include DEA Take Back Days, pharmacy kiosks, law enforcement kiosks, mail-back envelopes, and home disposal methods.
Pharmacy Times
JULY 19, 2025
Malesker, PharmD, FCCP, FCCM, FASHP, BCPS +1 More Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action. 16 At 12 weeks of treatment, placebo-subtracted reductions in sBP were -11.7 Jansen, PharmD Candidate , Mark A. The 50 mg dose achieved a 7.9
RX Note
JULY 5, 2025
Intravenous factor replacement therapy for the treatment or prevention of bleeding is the mainstay of treatment for haemophilia. Since the mid-1980s, plasma-derived concentrates have been manufactured with a variety of virus-inactivating techniques including dry heat, pasteurization and treatment with chemicals (e.g.
RX Note
JULY 5, 2025
Intravenous factor replacement therapy for the treatment or prevention of bleeding is the mainstay of treatment for haemophilia. Since the mid-1980s, plasma-derived concentrates have been manufactured with a variety of virus-inactivating techniques including dry heat, pasteurization and treatment with chemicals (e.g.
Expert insights. Personalized for you.
161 
Let's personalize your content